The patients had received on average eight different treatments following diagnosis of metastatic disease: all six patients had received a SERM; three had received a course of fulvestrant therapy, three a PI3K inhibitor, and three a CDK4/6 inhibitor (Full patient characteristics and treatment history are shown in Table 1 and Sup. This evidence concerns the gene CDK4 and metastatic neoplasm.